121 results about "Glycosphingolipid" patented technology

Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of α-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are provided, wherein the compounds are immunogenic compounds which serve as ligands for NKT (natural killer T) cells.

The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies may be coupled to a therapeutic agent and used in the treatment of cancer.

Novel prodrugs of amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.

Novel amino ceramide-like compounds (1) are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.

The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.

Novel prodrugs of amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.

The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies may be coupled to a therapeutic agent and used in the treatment of cancer.

The invention herein encompasses methods effective to stimulate epithelial cell proliferation and / or enhance epithelial moisturization and lubrication in a mammalian subject utilizing a composition comprising one or more inhibitors of beta -glucosidase activity or beta -glucocerebrosidase activity. The composition of the method may alternatively comprise a glycosphingolipid, particularly glucocerebroside, or a combination of the above inhibitor(s) and a glycosphingolipid. The method is effective to enhance the cosmetic appearance of skin and promote healing of skin and mucous membranes damaged or deficient from aging, traumatic wounds, photo-aging and a variety of atrophic conditions. The method may be applied to cells in culture. Also included in the invention is a composition comprising one or more inhibitors of beta -glucosidase and a glycosphingolipid useful to stimulate cell proliferation and enhance tissue moisturization and lubrication.

The invention belongs to the technical field of cosmetics, and particularly discloses double-layer essence with repair and anti-aging functions. The double-layer essence comprises, by weight, 1.0%-2.0% of PEG-40 (polyethylene glycol-40) hydrogenated castor oil, 5%-19% of methyl trimethicone, 4%-6% of dicaprylyl carbonate, 0.5%-1.5% of cetyl dimethicone, 0.5%-1.5% of helianthus annuus seed oil, 3%-9% of glycerin, 0.1%-0.15% of sodium hyaluronate, 0.5%-1.5% of myrothamnus flabellifolia leaf / stem extract, 1%-3% of polypeptides with palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, 0.5%-1.5% of lactobacillus ferment lysate, 1%-3% of glycosphingolipid, 0.8%-1% of mixtures of glycerol caprylate, p-hydroxy phenyl ethyl ketone and glyceryl laurate and the balance water. The double-layer essence has the advantages that the double-layer essence which is a novel ultralow-viscosity double-layer system is unique in structure and convenient to use; formulas and structures of the double-layer essence are optimized, and accordingly the double-layer essence is free of potential irritation and allergy sources such as perfume and preservatives, is in mild and non-irritant formulas and has the excellent repair and anti-aging functions.

Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.

The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.

The invention belongs to the technical field of cosmetics, and discloses a skin care substrate with long acting moisturizing and whitening effects and preparation and application of skin care substrate. The skin care substrate is prepared from the following components in mass percent: 10%-20% of tremella polysaccharide, 5%-10% of glycosphingolipid, 10%-20% of saccharide isomerate, 5%-10% of nicotinamide, 3%-6% of alpha-arbutin, 3%-6% of tranexamic acid, 1%-3% of ADS-Oligonol and balance of water. The skin care substrate disclosed by the invention has obvious long acting moisturizing and skin whitening effects and can make the skin moisturized and bright white by persistent use.

The present invention relates to a nutritional composition for infants and / or toddlers comprising a lipid component which has a lipid globules coated with polar lipids. The composition can be used to prevent obesity and / or improve body composition later in life. Said liquid comprises 10-50 wt % vegetable liquids based on the dry weight of the composition, and (i) 0.5-20 wt % phospholipids based on total weight or (ii) 0.6-25 wt % of polar lipids based on total lipids, wherein polar lipids are the sum of phospholipids, glycosphingolipids and cholesterol, and said composition comprises lipid globules with a core comprising said vegetable lipids and a coating comprising said phospholipids or polar lipids.

The invention discloses a Bose factor polypeptide anti-wrinkle eye cream and a preparation method thereof. The eye cream provides a conditioner with main active ingredients, and the conditioner comprises tocopheryl acetate, hexapeptide-9, palmitoyl pentapeptide-4, tripeptide-1, palmitoyl palmitoyl tripeptide-5, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, hydroxypropyl tetrahydropyrantriol (Bose factor), carnosine, glycosphingolipid, illicium verum callus culture filtrate and rosa damascena flower oil. The eye cream can effectively promote the generation of eye skin collagen, increase theelasticity and compactness of the skin, prevent wrinkles from deepening and repair the damaged barrier of the eye skin, and has the effects of wrinkle resistance, whitening and oxidation resistance.

This invention pertains to pharmaceutical formulations which comprise (i) a drug (e.g., an amphiphilic drug) (e.g., an anthracycline) (e.g., doxorubicin) and (ii) a short-chain sphingolipid (e.g., a short-chain glycosphingolipid or a short-chain sphingomyelin) (e.g., N-octanoyl-glucosylceramide, referred to as C8-GlcCer) (e.g., N-hexanoyl-sphingomyelin, referred to herein as C6-SM), and which provide improved drug delivery and efficacy. The short-chain sphingolipidis selected from compounds of the following formula: wherein: R1 is independently: an O-linked saccharide group; or an O-linked polyhydric alcohol group; or: R1 is independently: an O-linked (optionally N-(C1-4alkyl)-substituted amino)-C1-6alkyl-phosphate group; or an O-linked (polyhydric alcohol-substituted)-C1-6alkyl-phosphate group; R2 is independently C3-9alkyl, and is independently unsubstituted or substituted; R3 is independently C7-19alkyl, and is independently unsubstituted or substituted; R4 is independently —H, —OH, or —O—C1-4alkyl; RN is independently —H or C1-4alkyl; the bond marked with an alpha (α) is independently a single bond or a double bond; if the bond marked with an alpha (α) is a double bond, then R5 is —H; if the bond marked with an alpha (α) is a single bond, then R5 is —H or —OH; the carbon atom marked (*) is independently in an R-configuration or an S-configuration; the carbon atom marked (**) is independently in an R-configuration or an S-configuration; and pharmaceutically acceptable salts, solvates, esters, ethers, chemically protected forms thereof. In one embodiment, the pharmaceutical formulation is a liposomal pharmaceutical formulation prepared using a mixture of lipids comprising, at least, vesicle-forming lipids (e.g., phospholipids) (e.g., phosphatidylcholines) (e.g., fully hydrogenated soy phosphatidylcholine (HSPC)) (e.g., dipalmitoyl-phosphatidylcholine (DPPC)) and said short-chain sphingolipid, and optionally cholesterol and optionally a vesicle-forming lipid which is derivatized with a polymer chain (e.g., a phosphatidylethanolamine (PE) which is derivatized with polyethyleneglycol (PEG)) (e.g., N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (MPEG2000-DSPE). The present invention also pertains to methods for the preparation and use of such formulations.

The invention discloses a making method of 2'-OH derivant of alpha-galactose sphislycolipid, which comprises the following steps: synthesizing intermediate of alpha--galactose sphislycolipid through 3-O-benzyl-4, 6-O-benzal-2-O-p-methoxybenzyl p-methyl bentiamine and plant sphingol under N-iodosuccinimide and catalyst; introducing C18 alkyl, methyl, prenyl or alpha / beta connected galactose radical into naked -OH derivant on the intermediate without 2' p-methoxybenzyl; reducing azido group into amino group; acylating with aliphatic acid acted by accelerator; hydrogenating through palladium agent or liquid amino-metal sodium to reduce.

The invention discloses a facial cream for repairing cheek skin redness and preparation and application of the facial cream. The facial cream consists of the following raw materials in percentages bymass: a rhododendron ferrugineum extract, glycerinum, ectoine, superoxide dismutase, jojoba seed oil, oil of fruits of shorea robusta, sucrose palmitate, shea butter, glucan, sunflower seed oil, phytosterol, ceramide 1, ceramide 3, ceramide 6, squalane, polydimethylsiloxane, caprylic / capric triglyceride, Olivem 1000, polyglycerol-3 methyl glucose distearate, hydrogenated lecithin, cetostearyl alcohol, carbomer, xanthan gum, sodium hyaluronate, butanediol, rosa damascena flower water, panthenol, carnosine, ethoxydiglycol, a rhodiola rosea extract, chlorphenesin, caprylyl glycol, 1,2 pentanediol, perfluorodecalin, glycosphingolipid, sodium benzoate and water. The facial cream is used for repairing cheek skin redness for people in plateau areas.

The invention relates to the technical field of skin-care products, in particular to a composition containing a cryptomeria japonica bud extract for skin regeneration of a human face with steroid acnes and a preparation method of the composition. The composition comprises the following raw materials in parts by weight: 10-20 parts of the cryptomeria japonica bud extract, 20-40 parts of plant anti-sensitivity essence, 4-8 parts of glycosphingolipids, 20-30 parts of flowing spring factors, 5-15 parts of desert plant moisturizing factors, 15-25 parts of sodium hyaluronate and 4-8 parts of oat beta-glucan. The composition is good in antioxidant effect, awakens dormant cells, enables skin cells to slowly 'wake up', and has a rejuvenating effect; and furthermore, the skin can be safe against damage of an external environment, injury to sensitive skin by severe environment conditions can also be avoided, meanwhile, effects of astringing and controlling oil, and calming skin are achieved, andthus, the skin can be smooth and bright.

The invention discloses a method for specific separation and enrichment of acid sphingolipid and glycosphingolipid in human serum. The method realizes a sample preparation step of complex sphingolipidomics in serum through a titanium dioxide column separation technology, and comprises separation of neutral sphingolipid and the acid sphingolipid, and separation of the acid sphingolipid and the glycosphingolipid. The method provided by the invention can separate the neutral sphingolipid, the glycosphingolipid and the acid sphingolipid (such as phosphorylated sphingolipid and sulfatide), and consequently, realizes removal of nature determination and quantification to other minute amount even trace amount of sphingolipid (the glycosphingolipid and the phosphorylated sphingolipid) by high abundance neutral sphingolipid in mass spectrum. According to a titanium dioxide enrichment method in the method provided by the invention, eight biomarkers are detected from a clinical specimen, whereinthe biomarkers comprise ceramide in the neutral sphingolipid, S1P and C1p in the acid sphingolipid and the glycosphingolipid. And the eight biomarkers can distinguish Early and middle and advanced stage patients well.

The invention discloses a roe essence cream and a preparation method thereof. The roe essence cream comprises a component A, a component B and a component C, wherein the component A mainly comprises 28.90-87.05 parts of purified water and 3-10 parts of butanediol according to the weight ratio; the component B mainly comprises 3-10 parts of hydrogenated vegetable oil and 0.2-2.0 parts of squalane according to the weight ratio; and the component C mainly comprises 3-10 parts of aloe barbadensis leaf juice, 0.3-3.0 parts of dendrobium stem extract, 0.3-3.0 parts of aloe barbadensis leaf extract,0.3-3.0 parts of sophora japonica root extract, 0.3-3.0 parts of lycium chinense fruit extract and 0.1-1.0 parts of sturgeon caviar extract according to the weight ratio. The roe essence cream disclosed by the invention has the advantages that moisturizing and nourishing effects are achieved by using polyols, moisturizing factors, such as glycosphingolipids, trehalose and glycine betaine, and compositions of squalane, vitamin E and the like; under coordination of active components such as high-content roe essences, dendrobium stem and wolfberry extract, the skin texture is comprehensively improved, the damaged skin is repaired, sufficient nutrient is provided, the repairing and anti-oxidant ability is developed, and the skin ageing process is relieved in a targeted manner.

The invention relates to an anti-human glycosphingolipid Globo-H monoclonal antibody and a preparation method and application thereof. The anti-human glycosphingolipid Globo-H monoclonal antibody can specifically bind glycosphingolipid Globo-H in tumor tissues of liver cancer patients. The anti-human glycosphingolipid Globo-H monoclonal antibody has strong specific binding ability with human glycosphingolipid Globo-H, and can be well used in preparation of diagnostic reagents for diagnosis of liver cancer and the like.

The invention belongs to the technical field of cosmetics and particularly relates to cosmetic composition containing plant extracts. The cosmetic composition is mainly sourced from plants, and activecomponents extracted from the plants are natural, green and basically free of toxic and side effects; selected Avena sativa extracts are active substances having different oil-water partition coefficients, different molecular weights and different effects and extracted from different parts of Avena sativa with different extraction techniques; glycosphingolipids and glycolipids from wheat and hydrogenated lecithin from soybeans are selected for nanocrystallizing oil dissolution of Avena sativa active components with a high-pressure microfluidization technique, and transdermal absorption of theactive components is promoted; the cosmetic composition has multiple skin care effects of moisturizing skin, resisting allergy, relieving skin and improving skin barrier functions and is prepared from purified water, polyols, beta-glucan, Avena sativa kernel extract, Avena sativa stem extract, EDTA-2Na, glycosphingolipids, glycolipids, hydrogenated lecithin and Avena sativa kernel oil.

The invention relates to skin soothing and regenerating protein film cream and a preparation method of the skin soothing regenerating protein film cream, relating to the technical field of cosmetics. The skin soothing regenerating protein film cream is prepared from the following components: water, neopentyl glycol diheptanoate, butanediol, glycerol, an oat extract, fucogel-1, glycosphingolipids, wheat fine powder lipid, a plankton extract, a mirabilis jalapa extract, a hydrolyzed egg shell membrane and the like. The skin soothing regenerating protein film cream can permeate to the stratum corneum of skin and form a reticular protective film in the skin, so that the problems of ultraviolet ray invasion and skin dryness and ageing can be solved, meanwhile, the synthesis of collagens from fibroblasts is promoted, therefore, the formation of skin wrinkles is reduced, the skin aging is resisted, the skin elasticity is improved, the skin is enabled to be tender, fine and smooth, as well as full and plump, and is full of beautiful youth gloss, the outside contamination resistance of the skin is enhanced, the self-protection ability of the skin is enhanced, the cell ageing is prevented, and thus the skin ageing is delayed, the youthful vigor of the skin is recovered, the skin is tender and full, and the beautiful skin with the real lasting health is realized from inside to outside.

The invention discloses a probiotic mask, which comprises the following components by weight percentage: 1 to 5% of a fermentation product filtrate of bifida, 0.5 to 3% of a lactic acid bacteria fermentation lysate, 0.45 to 1.125% of alpha-glucan oligosaccharide, 0.5 to 5% of trehalose, 0.1 to 2% of a saccharide isomerate, and 0.1 to 2% of glycosphingolipid. The probiotic mask of the present invention is added with the fermentation product filtrate of bifida which is a probiotic product for repairing skin photoaging as well as a lactic acid bacteria fermentation lysate which is the probiotic product for promoting the exfoliation of the dead skin. The two probiotic products can repair damaged skin from the inside to outside; the addition of the moisturizing ingredients of alpha-glucan oligosaccharide, trehalose, the saccharide isomerate and glycosphingolipid can effectively moisturize the stratum corneum of the skin, and the combination of the probiotic product and the moisturizing ingredients enables the mask of the present invention to have a good skin repairing effect and a long-lasting moisturizing power.

Novel synthetic glycosphingolipids and pharmaceutical compositions containing such synthetic glycosphingolipids are described. Methods of making the novel synthetic glycosphingolipid compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.